Medicines and Mental Health Notices




3522

NEW ZEALAND GAZETTE

No. 172

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Inactivated influenza (split virion) 15 mcg of haemagglutinin for each of three recommended strains Solution for injection Connaught Laboratories Inc., Swiftwater, Pennsylvania, United States of America Fluzone
Codeine phosphate 15 mg, 30 mg, 60 mg Tablets Douglas Pharmaceuticals Limited, Technical Division, Mount Roskill, Auckland
Note: Not to be marketed as substitutable for any other codeine phosphate product as if the two (2) products were bioequivalent.
Ciprofloxacin hydrochloride 0.3% Ophthalmic solution S A Alcorn-Couvreur N V., Puurs, Belgium Ciloxan Eye Drops
Recombinant factor VIII 250IU/2.5 ml, 500IU/5 ml, 1000IU/10 ml Injection Bayer AG, Leverkusen, Germany Kogenate for injection
Sodium chloride 0.35% w/w, hydroxyethylcellulose 0.44% w/w Ophthalmic solution (eye drops) Smith & Nephew Pharmaceuticals Limited, Harold Hill, Romford, Essex, England Minims Artificial Tears
Bisoprolol hemifumarate 5 mg, 10 mg Tablets Cyanamid of Great Britain Limited, Gosport, Hants, England Monocor

Dated this 22nd day of November 1993.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

go10001


Consent to the Distribution of Changed Medicines

Pursuant to section 24 (5) of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines set out in the Schedule hereto:

Schedule

Name and Strength Form Name and Address of Manufacturer Proprietary Name (if any)
Interferon alpha-2c 3 mcg, 6 mcg, 15 mcg per ml Powder for reconstitution for injection Bender & Co GmbH, Vienna, Austria Berefor
Beractant 200 mg in 8 ml Intra-tracheal suspension Abbott Laboratories, North Chicago, Illinois, United States of America Survanta

Dated this 22nd day of November 1993.

C. LOVELACE, Director-General of Health, pursuant to delegation given by the Minister of Health on the 25th day of June 1993.

go10002


Mental Health (Compulsory Assessment and Treatment) Act 1992

Section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992

Pursuant to section 92 of the Mental Health (Compulsory Assessment and Treatment) Act 1992, I, James Christopher Lovelace, Director-General of Health, hereby give notice as follows:

Notice

  1. This notice referred to in the Schedule is hereby amended by replacing the words “Kay Ludovica Mead, manager of Tauranga” with the words “Katerina Goodwin, medical practitioner of Tauranga” in the right hand column of the Schedule to the notice specified in the Schedule to this notice.

Schedule

Date of Notice Reference
6 July 1993 New Zealand Gazette, 8 July 1993, No. 103, pages 1959 and 1960.

Dated at Wellington this 19th day of November 1993.

CHRISTOPHER LOVELACE, Director-General.

gn9985



Next Page →

PDF embedding disabled (Crown copyright)

View this page online at:


VUW Te Waharoa PDF NZ Gazette 1993, No 172


NZLII PDF NZ Gazette 1993, No 172





✨ LLM interpretation of page content

🏥 Consent to Distribution of New Medicine (continued from previous page)

🏥 Health & Social Welfare
22 November 1993
Medicines, Distribution, New Medicine, Schedule
  • C. Lovelace, Director-General of Health

🏥 Consent to the Distribution of Changed Medicines

🏥 Health & Social Welfare
22 November 1993
Medicines, Distribution, Changed Medicines, Schedule
  • C. Lovelace, Director-General of Health

🏥 Amendment to Mental Health Notice

🏥 Health & Social Welfare
19 November 1993
Mental Health, Notice Amendment, Schedule
  • Kay Ludovica Mead, Replaced in the Schedule
  • Katerina Goodwin (Medical Practitioner), Replacement in the Schedule

  • James Christopher Lovelace, Director-General of Health